NCT01207414

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 501 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	iloperidone	Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-09-22
• Last updated: 2013-03-15
• Results posted: 2013-03-15

Locations

59 sites across 1 country: United States